Linker effects on biological properties of 111In-labeled DTPA conjugates of a cyclic RGDfK dimer.

In this report, we present in vitro and in vivo evaluation of three 111 In-labeled DTPA conjugates of a cyclic RGDfK dimer: DTPA-Bn-SU016 (SU016 = E[c(RGDfK)] 2; DTPA-Bn = 2-( p-isothioureidobenzyl)diethylenetriaminepentaacetic acid), DTPA-Bn-E-SU016 ( E = glutamic acid) and DTPA-Bn-Cys-SU016 (Cys = cysteic acid). The integrin alpha vbeta 3 binding affinities of SU016, DTPA-Bn-SU016, DTPA-Bn-E-SU016, and DTPA-Bn-Cys-SU016 were determined to be 5.0 +/- 0.7 nM, 7.9 +/- 0.6 nM, 5.8 +/- 0.6 nM, and 6.9 +/- 0.9 nM, respectively, against 125 I-c(RGDyK) in binding to integrin alpha vbeta3, suggesting that E or Cys residue has little effect on the integrin alpha vbeta3 affinity of E[c(RGDfK)] 2. It was also found that the 111 In-labeling efficiency of DTPA-Bn-SU016 and DTPA-Bn-E-SU016 is 3-5 times better than that of DOTA analogues due to fast chelation kinetics and high-yield 111 In-labeling under mild conditions (e.g., room temperature). Biodistribution studies were performed using BALB/c nude mice bearing U87MG human glioma xenografts. 111 In-DTPA-Bn-SU016, 111 In-DTPA-Bn-E-SU016, and 111 In-DTPA-Bn-Cys-SU016 all displayed rapid blood clearance. Their tumor uptake was comparable between 0.5 and 4 h postinjection (p.i.) within experimental error. 111 In-DTPA-Bn-E-SU016 had a significantly lower ( p < 0.01) kidney uptake than 111 In-DTPA-Bn-SU016 and 111 In-DTPA-Bn-Cys-SU016. The liver uptake of 111 In-DTPA-Bn-SU016 was 1.69 +/- 0.18% ID/g at 24 h p.i., while the liver uptake values of 111 In-DTPA-Bn-E-SU016 and 111 In-DTPA-Bn-Cys-SU016 were 0.55 +/- 0.11% ID/g and 0.79 +/- 0.15% ID/g at 24 h p.i., respectively. Among the three 111 In radiotracers evaluated in this study, 111 In-DTPA-Bn-E-SU016 has the lowest liver and kidney uptake and the best tumor/liver and tumor/kidney ratios. Results from metabolism studies indicated that there is little metabolism (<10%) for three 111 In radiotracers at 1 h p.i. Imaging data showed that tumors can be clearly visualized at 4 h p.i. with good contrast in the tumor-bearing mice administered with 111 In-DTPA-Bn-E-SU016. It is concluded that using a glutamic acid linker can significantly improve excretion kinetics of the 111 In-labeled E[c(RGDfK)] 2 from liver and kidneys.

[1]  Shuang Liu,et al.  Coligand effects on the solution stability, biodistribution and metabolism of the (99m)Tc-labeled cyclic RGDfK tetramer. , 2008, Nuclear medicine and biology.

[2]  Young-Seung Kim,et al.  Evaluation of a 99mTc-Labeled Cyclic RGD Tetramer for Noninvasive Imaging Integrin αvβ3-Positive Breast Cancer , 2007 .

[3]  W. Oyen,et al.  Effects of linker variation on the in vitro and in vivo characteristics of an 111In-labeled RGD peptide. , 2007, Nuclear medicine and biology.

[4]  R. Sachleben,et al.  Radiolabeled divalent peptidomimetic vitronectin receptor antagonists as potential tumor radiotherapeutic and imaging agents. , 2007, Bioconjugate chemistry.

[5]  M. Walter,et al.  Influence of different spacers on the biological profile of a DOTA-somatostatin analogue. , 2007, Bioconjugate chemistry.

[6]  W. Oyen,et al.  Improved targeting of the αvβ3 integrin by multimerisation of RGD peptides , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[7]  Shuang Liu,et al.  Impact of PKM linkers on biodistribution characteristics of the 99mTc-labeled cyclic RGDfK dimer. , 2006, Bioconjugate chemistry.

[8]  P. Yalamanchili,et al.  Structure-activity relationships of 111In- and 99mTc-labeled quinolin-4-one peptidomimetics as ligands for the vitronectin receptor: potential tumor imaging agents. , 2006, Bioconjugate chemistry.

[9]  Shuang Liu Radiolabeled Multimeric Cyclic RGD Peptides as Integrin αvβ3 Targeted Radiotracers for Tumor Imaging , 2006 .

[10]  Bing Jia,et al.  99mTc-Labeled Cyclic RGDfK Dimer: Initial Evaluation for SPECT Imaging of Glioma Integrin αvβ3 Expression , 2006 .

[11]  S. Gambhir,et al.  Quantitative PET Imaging of Tumor Integrin αvβ3 Expression with 18F-FRGD2 , 2006 .

[12]  S. Mohammed,et al.  Effect of coligands on biodistribution characteristics of ternary ligand 99mTc complexes of a HYNIC-conjugated cyclic RGDfK dimer. , 2005, Bioconjugate chemistry.

[13]  S. Gambhir,et al.  microPET Imaging of Glioma Integrin αvβ3 Expression Using 64Cu-Labeled Tetrameric RGD Peptide , 2005 .

[14]  M. Schwaiger,et al.  Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[15]  Horst Kessler,et al.  Noninvasive Visualization of the Activated αvβ3 Integrin in Cancer Patients by Positron Emission Tomography and [18F]Galacto-RGD , 2005, PLoS medicine.

[16]  S. Robinson,et al.  Radiolabeled Integrin αvβ3 Antagonists as Radiopharmaceuticals for Tumor Radiotherapy , 2005 .

[17]  Hans-Jü Rgen Wester Molecular Targeting with Peptides or Peptide-Polymer Conjugates: Just a Question of Size? , 2005 .

[18]  Ryan Park,et al.  MicroPET imaging of breast cancer alphav-integrin expression with 64Cu-labeled dimeric RGD peptides. , 2004, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.

[19]  W. Oyen,et al.  Improved tumor targeting of radiolabeled RGD peptides using rapid dose fractionation. , 2004, Cancer biotherapy & radiopharmaceuticals.

[20]  R. Haubner,et al.  Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies. , 2004, Current pharmaceutical design.

[21]  H. Jin,et al.  Integrins: roles in cancer development and as treatment targets , 2004, British Journal of Cancer.

[22]  I. Pastan,et al.  Comparative biodistribution of indium- and yttrium-labeled B3 monoclonal antibody conjugated to either 2-(p-SCN-Bz)-6-methyl-DTPA (1 B4M-DTPA) or 2-(p-SCN-Bz)-1,4,7,10-tetraazacyclododecane tetraacetic acid (2B-DOTA) , 1994, European Journal of Nuclear Medicine.

[23]  M. Schwaiger,et al.  Chemoselective pre-conjugate radiohalogenation of unprotected mono- and multimeric peptides via oxime formation , 2004 .

[24]  M. Schwaiger,et al.  [18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. , 2004, Bioconjugate chemistry.

[25]  Ryan Park,et al.  MicroPET and autoradiographic imaging of breast cancer alpha v-integrin expression using 18F- and 64Cu-labeled RGD peptide. , 2004, Bioconjugate chemistry.

[26]  J. Bading,et al.  Pharmacokinetics and tumor retention of 125I-labeled RGD peptide are improved by PEGylation. , 2004, Nuclear medicine and biology.

[27]  Peter S. Conti,et al.  MicroPET imaging of brain tumor angiogenesis with 18F-labeled PEGylated RGD peptide , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[28]  J. Folkman,et al.  Fundamental concepts of the angiogenic process. , 2003, Current molecular medicine.

[29]  M. Schwaiger,et al.  Radiotracer-based strategies to image angiogenesis. , 2003, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[30]  S. Robinson,et al.  Design, synthesis, and evaluation of radiolabeled integrin αvβ3 receptor antagonists for tumor imaging and radiotherapy , 2003 .

[31]  Horst Kessler,et al.  Multimeric cyclic RGD peptides as potential tools for tumor targeting: solid-phase peptide synthesis and chemoselective oxime ligation. , 2003, Chemistry.

[32]  L. Knight,et al.  Radiopharmaceuticals for targeting the angiogenesis marker αvβ3 , 2003 .

[33]  S. Robinson,et al.  Integrin alphavbeta3 directed radiopharmaceuticals for tumor imaging , 2003 .

[34]  Milind Rajopadhye,et al.  Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model. , 2002, Cancer research.

[35]  Manfred Schwab,et al.  Arginine-glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in vivo. , 2002, Cancer research.

[36]  W. Oyen,et al.  Tumor Targeting with Radiolabeled v 3 Integrin Binding Peptides in a Nude Mouse Model , 2002 .

[37]  S. Liu,et al.  Synthesis and characterization of two (111)In-labeled DTPA-peptide conjugates. , 2001, Bioconjugate chemistry.

[38]  M. Rajopadhye,et al.  (90)Y and (177)Lu labeling of a DOTA-conjugated vitronectin receptor antagonist useful for tumor therapy. , 2001, Bioconjugate chemistry.

[39]  J. Barrett,et al.  99mTc-labeling of a hydrazinonicotinamide-conjugated vitronectin receptor antagonist useful for imaging tumors. , 2001, Bioconjugate chemistry.

[40]  M Schwaiger,et al.  Tumor angiogenesis targeting using imaging agents. , 2001, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[41]  Sibylle Ziegler,et al.  Noninvasive Imaging of αvβ3 Integrin Expression Using 18F-labeled RGD-containing Glycopeptide and Positron Emission Tomography , 2001 .

[42]  M Schwaiger,et al.  Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[43]  M. Rajopadhye,et al.  Isomerism and solution dynamics of (90)Y-labeled DTPA--biomolecule conjugates. , 2001, Bioconjugate chemistry.

[44]  Shuang Liu,et al.  Bifunctional chelators for therapeutic lanthanide radiopharmaceuticals. , 2001, Bioconjugate chemistry.

[45]  Horst Kessler,et al.  Radiolabeled αvβ3 Integrin Antagonists: A New Class of Tracers for Tumor Targeting , 1999 .

[46]  T. Waldmann,et al.  Similarities and differences in 111In- and 90Y-labeled 1B4M-DTPA antiTac monoclonal antibody distribution. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[47]  S. Mirzadeh,et al.  Physical parameters and biological stability of yttrium(III) diethylenetriaminepentaacetic acid derivative conjugates. , 1998, Journal of medicinal chemistry.

[48]  L. Jennings,et al.  Integrin-mediated signal transduction , 1998, Cellular and Molecular Life Sciences CMLS.

[49]  P. Smith-Jones,et al.  Synthesis and characterisation of [90Y]-Bz-DTPA-oct: a yttrium-90-labelled octreotide analogue for radiotherapy of somatostatin receptor-positive tumours. , 1998, Nuclear medicine and biology.

[50]  R L Juliano,et al.  Integrin signaling and cell growth control. , 1998, Current opinion in cell biology.

[51]  E P Krenning,et al.  Internalization of radiolabelled [DTPA0]octreotide and [DOTA0,Tyr3]octreotide: peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy. , 1998, Nuclear medicine communications.

[52]  I. Pastan,et al.  Evaluation of the serum stability and in vivo biodistribution of CHX-DTPA and other ligands for yttrium labeling of monoclonal antibodies. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.